DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Lucidin primeveroside, 29706-59-0, Lucidin 3-o-primeveroside, 1-hydroxy-2-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyanthracene-9,10-dione, Lucidin 3-o-beta-primveroside, 1-hydroxy-2-(hydroxymethyl)-3-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2-yl)oxy)anthracene-9,10-dione

Molecular Formula

C₂₆H₂₈O₁₄

Molecular Weight

564.5 g/mol

InChI Key

NVKNRXOMCYTFJF-WFLOGZPDSA-N

1-hydroxy-2-(hydroxymethyl)-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxan-2-yl]oxy}anthracene-9,10-dione is a natural product found in Rubia argyi, Rubia yunnanensis, and other organisms with data available.

1 2D Structure

Lucidinprimeveroside

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-hydroxy-2-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyanthracene-9,10-dione

2.1.2 InChI

InChI=1S/C26H28O14/c27-6-12-14(5-11-16(19(12)31)18(30)10-4-2-1-3-9(10)17(11)29)39-26-24(36)22(34)21(33)15(40-26)8-38-25-23(35)20(32)13(28)7-37-25/h1-5,13,15,20-28,31-36H,6-8H2/t13-,15-,20+,21-,22+,23-,24-,25+,26-/m1/s1

2.1.3 InChI Key

NVKNRXOMCYTFJF-WFLOGZPDSA-N

2.1.4 Canonical SMILES

C1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(C(=C4C(=C3)C(=O)C5=CC=CC=C5C4=O)O)CO)O)O)O)O)O)O

2.1.5 Isomeric SMILES

C1[C@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(C(=C4C(=C3)C(=O)C5=CC=CC=C5C4=O)O)CO)O)O)O)O)O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Lucidin 3-o-beta-primveroside

2. Lucidin 3-o-primveroside

2.2.2 Depositor-Supplied Synonyms

1. Lucidin Primeveroside

2. 29706-59-0

3. Lucidin 3-o-primeveroside

4. 1-hydroxy-2-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyanthracene-9,10-dione

5. Lucidin 3-o-beta-primveroside

6. 1-hydroxy-2-(hydroxymethyl)-3-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2-yl)oxy)anthracene-9,10-dione

7. 9,10-anthracenedione, 1-hydroxy-2-(hydroxymethyl)-3-[(6-o-beta-d-xylopyranosyl-beta-d-glucopyranosyl)oxy]-

8. Ccris 4532

9. Lucidin 3-o-primveroside

10. Lucidin Primevoroside

11. Lucidin-primeveroside

12. Chembl521217

13. Schembl23522435

14. Dtxsid40952155

15. Hy-n8022

16. Zinc42878492

17. Glucopyranoside, 4-hydroxy-3-(hydroxymethyl)-2-anthraquinonyl 6-o-beta-d- Xylopyranosyl-, Beta-d-

18. Cs-0138995

19. E88947

20. 1-hydroxy-2-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxytetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-anthracene-9,10-dione

21. 4-hydroxy-3-(hydroxymethyl)-9,10-dioxo-9,10-dihydroanthracen-2-yl 6-o-pentopyranosylhexopyranoside

22. Ncgc00384986-01!1-hydroxy-2-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyanthracene-9,10-dione

2.3 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₈O₁₄
Molecular Weight	564.5 g/mol
XLogP3	-2.1
Hydrogen Bond Donor Count	8
Hydrogen Bond Acceptor Count	14
Rotatable Bond Count	6
Exact Mass	564.14790556 g/mol
Monoisotopic Mass	564.14790556 g/mol
Topological Polar Surface Area	233 Å²
Heavy Atom Count	40
Formal Charge	0
Complexity	918
Isotope Atom Count	0
Defined Atom Stereocenter Count	9
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Lucidinprimeveroside manufacturers, exporters & distributors on PharmaCompass

Lucidinprimeveroside

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DIGITAL CONTENT

1 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?